thalidomide - Universidade Nova de Lisboa
... thalidomide, marked he beginning of the end, leading the makers of the drug to finally stop distribution within Germany. Other countries followed and, by March of 1962, the drug was banned in most countries where it was previously sold. ...
... thalidomide, marked he beginning of the end, leading the makers of the drug to finally stop distribution within Germany. Other countries followed and, by March of 1962, the drug was banned in most countries where it was previously sold. ...
Wilex licenses Anti-cancer Antibody from VU University Medical
... Munich (Germany) and Amsterdam (The Netherlands), 15 May 2003. Wilex AG, Munich, a biopharmaceutical company dedicated to the development of novel cancer therapies and VU University Medical Center Amsterdam (VUmc) announced today that Wilex has acquired an exclusive licence from VUmc for the monoclo ...
... Munich (Germany) and Amsterdam (The Netherlands), 15 May 2003. Wilex AG, Munich, a biopharmaceutical company dedicated to the development of novel cancer therapies and VU University Medical Center Amsterdam (VUmc) announced today that Wilex has acquired an exclusive licence from VUmc for the monoclo ...
Intra-Cellular Therapies, Inc.
... Psychiatry at the Columbia University College of Physicians and Surgeons, and Director of the New York State Psychiatric Institute, will present a summary of the ITI-007-005 trial results in an oral presentation. About the ITI-007-005 Phase 2 Clinical Trial Design The Phase 2 clinical trial, ITI-007 ...
... Psychiatry at the Columbia University College of Physicians and Surgeons, and Director of the New York State Psychiatric Institute, will present a summary of the ITI-007-005 trial results in an oral presentation. About the ITI-007-005 Phase 2 Clinical Trial Design The Phase 2 clinical trial, ITI-007 ...
July 15, 2009
... recommend titrating beta-blockers to doses used in published randomized trials. • Achieving this goal is often challenging in practice, because the adverse effects of beta-blockade are largely dose-related. • To explore whether the benefits of beta-blockade for heart failure relates to the reduction ...
... recommend titrating beta-blockers to doses used in published randomized trials. • Achieving this goal is often challenging in practice, because the adverse effects of beta-blockade are largely dose-related. • To explore whether the benefits of beta-blockade for heart failure relates to the reduction ...
VIEWS & REVIEWS - BMJ Press Releases
... 2008-12 NSDUH (n=191 382) Hendricks et al found that ever having used psychedelics was associated with a significantly reduced risk of suicide.11 These results have been broadly replicated in another sample of 135 095 randomly selected US adults.12 ...
... 2008-12 NSDUH (n=191 382) Hendricks et al found that ever having used psychedelics was associated with a significantly reduced risk of suicide.11 These results have been broadly replicated in another sample of 135 095 randomly selected US adults.12 ...
Pharmacology 14b – Adverse Drug Reactions
... A pseudoallergy is a bodily reaction with symptoms similar to that of an allergy but it lacks immunological specificity. Causes of Adverse Drugs Reactions • Antibiotics • Antineoplastics • Anticoagulants • Cardiovascular drugs • Hypoglyceamics • Antihypertensives • NSAID/Analgesics • CNS drugs Detec ...
... A pseudoallergy is a bodily reaction with symptoms similar to that of an allergy but it lacks immunological specificity. Causes of Adverse Drugs Reactions • Antibiotics • Antineoplastics • Anticoagulants • Cardiovascular drugs • Hypoglyceamics • Antihypertensives • NSAID/Analgesics • CNS drugs Detec ...
a review on drug approval process for us, europe and india
... different regulatory requirements for approval of new drug. For marketing authorization application (MAA) a single regulatory approach is applicable to various countries is almost a difficult task. Therefore it is necessary to have knowledge about regulatory requirement for MAA of each country. The ...
... different regulatory requirements for approval of new drug. For marketing authorization application (MAA) a single regulatory approach is applicable to various countries is almost a difficult task. Therefore it is necessary to have knowledge about regulatory requirement for MAA of each country. The ...
Journal 12/6 - Lake Crystal
... to be prescribed by a doctor • OTC drugs- drugs designed specifically for medical uses, especially cases that are not as serious; available for the ...
... to be prescribed by a doctor • OTC drugs- drugs designed specifically for medical uses, especially cases that are not as serious; available for the ...
Document
... additive or synergistic effect for ziconotide • Ziconotide successfully produced analgesia in patients with metastatic cancer pain, chronic post-surgical pain, and CIPN. ...
... additive or synergistic effect for ziconotide • Ziconotide successfully produced analgesia in patients with metastatic cancer pain, chronic post-surgical pain, and CIPN. ...
N
... When available, the results al in vitro :usceOliDBity lost results lot antimicrobial drugs used in rr;i0ern hospitals Should be provided t0 the physician a5 periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from suscep ...
... When available, the results al in vitro :usceOliDBity lost results lot antimicrobial drugs used in rr;i0ern hospitals Should be provided t0 the physician a5 periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from suscep ...
Light therapy for cold sores
... device three times a day for two days . 1072nm narrowband light is not visible to the naked eye, thus patients were not aware of which device they received. Patients were required to have a history of recurrent herpes labialis (defined as at least three episodes in the previous year). Cold sores aff ...
... device three times a day for two days . 1072nm narrowband light is not visible to the naked eye, thus patients were not aware of which device they received. Patients were required to have a history of recurrent herpes labialis (defined as at least three episodes in the previous year). Cold sores aff ...
Adriane Fugh-Berman MD PharmedOut.org Georgetown University
... and changed — about the disease itself, as well as individual treatments.” Barnes S. http://www.pmlive.com/find_an_article/allarticles/categories/ General/2008/june/cramping_your_style ...
... and changed — about the disease itself, as well as individual treatments.” Barnes S. http://www.pmlive.com/find_an_article/allarticles/categories/ General/2008/june/cramping_your_style ...
Seikagaku Submits New Drug Application for SI
... Seikagaku Submits New Drug Application for SI-6603 in Japan for Treatment of Lumbar Disc Herniation Seikagaku Corporation (Tokyo, Japan) hereby announces that it has submitted a new drug application (NDA) for SI-6603 (generic name: condoliase), indicated for the treatment of lumbar disc herniation, ...
... Seikagaku Submits New Drug Application for SI-6603 in Japan for Treatment of Lumbar Disc Herniation Seikagaku Corporation (Tokyo, Japan) hereby announces that it has submitted a new drug application (NDA) for SI-6603 (generic name: condoliase), indicated for the treatment of lumbar disc herniation, ...
AEDs - BC Epilepsy Society
... Percentages were based on the number of patients in each modal dose group with an evaluable responder status during the relative time interval. Responders were defined as patients who experienced ≥50% reduction in seizure frequency during the time interval from baseline (where baseline was from the ...
... Percentages were based on the number of patients in each modal dose group with an evaluable responder status during the relative time interval. Responders were defined as patients who experienced ≥50% reduction in seizure frequency during the time interval from baseline (where baseline was from the ...
- Celon Pharma
... The objective of the CELONKO project is preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs). As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight agains ...
... The objective of the CELONKO project is preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs). As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight agains ...
In vitro susceptibility testing and totally drug-resistant tuberculosis
... drug-resistant tuberculosis To the Editor: We find the article by MIGLIORI et al. [1], on extensively drug-resistant tuberculosis (XDR-TB), very informative and would like to commend them for the excellent meta-analysis. Without any doubt, XDR-TB is an extensive global problem; the use of the lower ...
... drug-resistant tuberculosis To the Editor: We find the article by MIGLIORI et al. [1], on extensively drug-resistant tuberculosis (XDR-TB), very informative and would like to commend them for the excellent meta-analysis. Without any doubt, XDR-TB is an extensive global problem; the use of the lower ...
Basic Principles of Pharmacology
... man unless there is a high suspicion that the drug could be carcinogenic e.g. suspicion of mutagenicity; highly reactive groups on drug; histopathological abnormalities… Required if the use of drug in man for more than one year or +ve mutagenic test ...
... man unless there is a high suspicion that the drug could be carcinogenic e.g. suspicion of mutagenicity; highly reactive groups on drug; histopathological abnormalities… Required if the use of drug in man for more than one year or +ve mutagenic test ...
Result - WHO archives
... Setting: 100 MoPH hospitals, 1 university hospital, and 4 defense hospitals. Intervention: Four antimicrobials and two cardiovascular drugs were selected as tracers. DUE package for the 6 drugs, (consist of evaluation criteria of 6 drugs use, guideline on DUE procedure, drug order forms, data collec ...
... Setting: 100 MoPH hospitals, 1 university hospital, and 4 defense hospitals. Intervention: Four antimicrobials and two cardiovascular drugs were selected as tracers. DUE package for the 6 drugs, (consist of evaluation criteria of 6 drugs use, guideline on DUE procedure, drug order forms, data collec ...
... failure, libido decreased, prostatitis, scrotal pain, testicular pain, testicular swelling, urinary hesitation, urinary retention, urethral pain, and urine flow decreased. Other Adverse Reactions Observed During Clinical Trials of Savella in Fibromyalgia-Following is a list of frequent (those occurr ...
Etotio
... skin reactions that can be fatal in some cases and should be advised to stop treatment in case of rash or any other signs of hypersensitivity. Thiocolchicoside that is included in the contents of ETOTIO can accelerate the attacks especially in epileptic patients or in those with a risk for attacks. ...
... skin reactions that can be fatal in some cases and should be advised to stop treatment in case of rash or any other signs of hypersensitivity. Thiocolchicoside that is included in the contents of ETOTIO can accelerate the attacks especially in epileptic patients or in those with a risk for attacks. ...
Who made the ruling? What was the vote? What was the award?
... Ms. Levine’s suffering began in the spring of 2000 when, suffering from a migraine, she visited a local clinic for a treatment she had received many times: Demerol for pain and Phenergan for nausea. If Phenergan is exposed to arterial blood, it causes swift and irreversible gangrene. Therefore, it ...
... Ms. Levine’s suffering began in the spring of 2000 when, suffering from a migraine, she visited a local clinic for a treatment she had received many times: Demerol for pain and Phenergan for nausea. If Phenergan is exposed to arterial blood, it causes swift and irreversible gangrene. Therefore, it ...
Bad Pharma
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.